Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

Stopped Development program terminated and the decision was not due to any safety concerns.

Conditions

• Relapsed/Refractory Large B-cell Lymphoma

Interventions

• DRUG: Cyclophosphamide
• DRUG: Fludarabine
• BIOLOGICAL: Lenzilumab
• BIOLOGICAL: Axicabtagene Ciloleucel

Sponsor

Kite, A Gilead Company

Collaborators

• [object Object]